Skip to Content
Merck
All Photos(1)

Documents

1356756

USP

Lamotrigine

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H7Cl2N5
CAS Number:
Molecular Weight:
256.09
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lamotrigine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Anticonvulsant.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

USP issued SDS can be found here.
Sales restrictions may apply.

related product

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of Permeation enhancers on diffusion of lamotrigine drug through cellophane membrane.
Rao, Vinay, et al.
American Journal of Advanced Drug Delivery, 1.4, 606-610 (2013)
Philip J Wiffen et al.
The Cochrane database of systematic reviews, 12(12), CD006044-CD006044 (2013-12-04)
This is an update of the original Cochrane review entitled Lamotrigine for acute and chronic pain published in Issue 2, 2007, and updated in Issue 2, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain
Zhi-fei Wang et al.
Acta pharmacologica Sinica, 32(12), 1433-1445 (2011-11-08)
The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder. However, accumulating evidence suggests that these drugs have broad neuroprotective properties and may therefore be promising therapeutic agents for the treatment of neurodegenerative diseases, including stroke.
Jennifer G Reid et al.
The Journal of clinical psychiatry, 74(7), 675-684 (2013-08-16)
Owing to the prevalence of medication side effects and treatment resistance, prescribers often consider off-label uses of US Food and Drug Administration (FDA)-approved agents for the treatment of persistent symptoms. The authors review the available literature on the FDA-approved and
Jacqueline A French et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(1), 176-184 (2011-12-06)
The efficacy and safety of lamotrigine extended-release tablets (LTG XR) as monotherapy for partial seizures were evaluated using the conversion-to-monotherapy design, and historical data as the control. This methodology was recently approved by the United States Food and Drug Administration

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service